← United States · Coverage record
US · SEC FORM 4
Barinthus Biotherapeutics plc.
BRNS · — · CIK 0001828185 · Healthcare
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
11 Form 4 transaction lines observed in the same window
0 sales · 11 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 3 additional owner(s) remain in Form 4 evidence.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-06-26 · Scheeren Joseph.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2023-06-26 | Scheeren Joseph | Purchase (P) | Ordinary Shares | 10,000 | USD 2.44 | USD 24,400 | SEC filing ↗ |
| 2023-05-25 | Wright Robin | Purchase (P) | Ordinary Shares | 13,750 | USD 2.66 | USD 36,575 | SEC filing ↗ |
| 2022-04-01 | Scheeren Joseph | Purchase (P) | Ordinary Shares | 10,000 | USD 5.09 | USD 50,900 | SEC filing ↗ |
| 2022-03-31 | Hammacher Alex | Purchase (P) | Ordinary Shares | 2,000 | USD 5.14 | USD 10,280 | SEC filing ↗ |
| 2021-12-31 | Hammacher Alex | Purchase (P) | Ordinary Shares | 1,000 | USD 10.86 | USD 10,860 | SEC filing ↗ |
| 2021-12-22 | Wright Robin | Purchase (P) | Ordinary Shares | 10,000 | USD 9.97 | USD 99,700 | SEC filing ↗ |
| 2021-05-04 | Wright Robin | Purchase (P) | Ordinary Shares | 14,000 | USD 17.00 | USD 238,000 | SEC filing ↗ |
| 2021-05-04 | Scheeren Joseph | Purchase (P) | Ordinary Shares | 3,000 | USD 17.00 | USD 51,000 | SEC filing ↗ |
| 2021-05-04 | Phillips Anne M. | Purchase (P) | Ordinary Shares | 3,000 | USD 17.00 | USD 51,000 | SEC filing ↗ |
| 2021-05-04 | Oxford Sciences Innovation plc | Purchase (P) | American Depositary Shares | 600,000 | USD 17.00 | USD 10,200,000 | SEC filing ↗ |
| 2021-05-04 | Griffiths Graham | Purchase (P) | Ordinary Shares | 100 | USD 17.00 | USD 1,700 | SEC filing ↗ |
| 2021-05-04 | Ellis Christopher | Purchase (P) | Ordinary Shares | 75 | USD 17.00 | USD 1,275 | SEC filing ↗ |
| 2021-05-04 | DAWES KAREN A | Purchase (P) | Ordinary Shares | 1,700 | USD 17.00 | USD 28,900 | SEC filing ↗ |
| 2021-04-30 | M&G INVESTMENT MANAGEMENT LTD | Purchase (P) | American Depositary Shares | 125,000 | USD 14.40 | USD 1,800,000 | SEC filing ↗ |
Form 4 evidence
11 transaction lines in the latest 365-day window; 62 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | Oxford Science Enterprises plc | U (U) | Ordinary Shares | 8,797,770 | USD 0.11 | USD 967,755 | SEC filing ↗ |
| 2026-09-09 | Wright Robin | D (D) | Ordinary Shares | 48,256 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | Scheeren Joseph | D (D) | Ordinary Shares | 23,000 | USD — | USD — | SEC filing ↗ |
Show recent Form 4 evidence (10 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | Oxford Science Enterprises plc | U (U) | Ordinary Shares | 8,797,770 | USD 0.11 | USD 967,755 | SEC filing ↗ |
| 2026-09-09 | Wright Robin | D (D) | Ordinary Shares | 48,256 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | Scheeren Joseph | D (D) | Ordinary Shares | 23,000 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | Phillips Anne M. | D (D) | Ordinary Shares | 3,000 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | Morgon Pierre A. | D (D) | Ordinary Shares | 10,506 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | Hooftman Leon | D (D) | Ordinary Shares | 361,530 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | Hooftman Leon | Award / grant (A) | Ordinary Shares | 361,530 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | Hammacher Alex | D (D) | Ordinary Shares | 3,000 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | Enright William | D (D) | Ordinary Shares | 1,243,377 | USD — | USD — | SEC filing ↗ |
| 2026-09-09 | DAWES KAREN A | D (D) | Ordinary Shares | 1,700 | USD — | USD — | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | BRNS |
| CIK | 0001828185 |
| Sector | Healthcare |
| Industry | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | — |
Data coverage
| Local Form 4 history | 62 transaction lines from 2021-04-29 to 2026-09-09 14 P purchase lines · 15 S sale lines · 33 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.